Amgen Inc.
HealthcareNASDAQ:AMGN · NASDAQ Global Select
-$0.45 today
Vol 1.16M · Avg 2.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
89.1%
avg 74.3%
ROIC
13.2%
avg 12.3%
ROA
8.5%
avg 9.0%
Analysis
ROE is currently the strongest return metric at 89.1% versus its period average of 74.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert A. Bradway | Chairman & CEO | $6.69M | — | 63 | $26,251.00 | <0.01% |
James E. Bradner | EVP of Research & Development, Artificial Intelligence and Data | $3.84M | — | 54 | $2,211.00 | <0.01% |
David Reese | Executive Vice President & Chief Technology Officer | $3.49M | — | 63 | $42,256.00 | <0.01% |
Peter H. Griffith | Executive Vice President & Chief Financial Officer | $3.31M | — | 67 | $50,150.00 | <0.01% |
Murdo Gordon | EVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | $3.22M | — | 59 | $51,222.00 | <0.01% |
Esteban Santos | Executive Vice President of Operations | $3.01M | — | 58 | $82,847.00 | 0.02% |
Jonathan Graham | Executive Vice President, General Counsel & Secretary | $2.44M | — | 65 | $39,712.00 | <0.01% |
Sam Guhan | Senior Vice President of Global Engineering | — | — | — | — | — |
Som Chattopadhyay | Senior Vice President of Global Business Solutions & National Executive | — | — | — | — | — |
Andrew H. Martin | Senior VP & GM of U.S. Business Operations | — | — | — | $50,150.00 | <0.01% |
Jasper van Grunsven | Senior Vice President of Rare Disease, Global Commercial Capabilities & Innovation | — | — | — | — | — |
Casey Capparelli | Executive Director of Investor Relations | — | — | — | — | — |
Howard Y. Chang | Senior Vice President of Global Research & Chief Scientific Officer | — | — | — | — | — |
Matthew C. Busch | Chief Accounting Officer & Vice President of Finance | — | — | 51 | $13,848.00 | <0.01% |
Scott Skellenger | Senior Vice President & Chief Information Officer | — | — | — | — | — |
Nancy A. Grygiel | Senior Vice President of Worldwide Compliance & Business Ethics and Chief Compliance Officer | — | — | 58 | $7,330.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
7
$13.53M
Net Sentiment
$13.53M
Net selling
Most Active
Grygiel Nancy A.
3 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 7 sells worth $13.53M over the last 12 months. That adds up to net selling of $13.53M. Grygiel Nancy A. was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +18.0% | +7.7% (15yr)5 analysts |
| Revenue | N/A | N/A | +7.9% | +4.6% (15yr)13 analysts |
| Net Income | N/A | N/A | +16.9% | +5.2% (15yr)13 analysts |
| EBIT | N/A | N/A | +14.9% | +3.0% (15yr)13 analysts |
Analysis
Recent growth has been strongest in EPS at +18.0% over three years. Forward estimates point to EPS at +7.7% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.18B
Novartis AG
NYSE:NVS
$292.74B
Novo Nordisk A/S
NYSE:NVO
$196.77B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.57B
Pfizer Inc.
NYSE:PFE
$149.27B
Danaher Corporation
NYSE:DHR
$127.55B
Bristol-Myers Squibb Company
NYSE:BMY
$116.63B
GSK plc
NYSE:GSK
$106.58B
Sanofi
NASDAQ:SNY
$106.44B
Boston Scientific Corporation
NYSE:BSX
$69.90B
Who manages AMGN?
Amgen Inc. (AMGN) lists 16 active executives. The top listed executive is Peter H. Griffith, Executive Vice President & Chief Financial Officer.
Are AMGN insiders buying or selling?
Recent insider activity shows net buying of $54.57M.
Explore More
Continue the stock analysis
Jump to another research area for this company.